Fig. 5

TGFBR2 serves as a prognostic factor for ccRCCs. A and B Higher TGFBR2 expression predicts longer OS and DFS in the TCGA cohort of ccRCC patients. C and D Multivariate analyses show the impacts of TGFBR2 on OS and DFS in the TCGA cohort of ccRCC patients, respectively. E-G Higher TGFBR2 expression is associated with longer overall survival (OS) in the TMA cohort of ccRCC patients. The representative immunohistochemical results of GABPA-strong and weak tumors and correlation with TGFBR2 (E and F). Scale bars: 100 µm. (H and I) Patients with both lower GABPA and TGFBR2 had shortest OS and DFS in the TCGA ccRCC cohort